Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2025 22:00 ET | Source: EnGeneIC

EnGeneIC launches groundbreaking new Australian trial for innovative cancer therapy, with international trial site in Singapore to follow

First Patient dosed in Phase I/IIa Basket Trial for Solid Tumours at Mater Hospital, North SydneyRecruitment to open this month at Frankston Hospital, VictoriaFurther site to follow at Curie Oncology,...
October 01, 2024 08:00 ET | Source: EnGeneIC

Distinguished Oncologist, Professor Daniel Von Hoff joins the Scientific/Clinical Advisory Board of EnGeneIC Cancer Therapeutics

EnGeneIC appoints Dr. Daniel Van Hoff to its Scientific Advisory Board to advise on clinical oncology programs, including upcoming PDAC trial.
June 06, 2024 21:13 ET | Source: EnGeneIC

EnGeneIC and Singapore Institute of Advanced Medicine Holdings Forge Strategic Partnership to Revolutionise Cancer Treatment in Asia

SYDNEY, Australia, June 06, 2024 (GLOBE NEWSWIRE) -- EnGeneIC, a clinical-stage biopharmaceutical company pioneering the development of a First-in-Class targeted nanocell for cancer therapy has...
December 07, 2023 19:51 ET | Source: EnGeneIC

EnGeneIC granted FDA “Fast-Track” Designation for Novel Armed Nanocell Drug Conjugate (ANDC) Pancreatic Cancer Therapeutic

EneneIC has been granted Fast Track designation for use of its novel Armed Nanocell Drug Conjugate (ANDC) in PDAC patients.
November 26, 2023 23:37 ET | Source: EnGeneIC

EnGeneIC’s breakthrough Armed Nanocell Drug Conjugate (ANDC) treatment shows promising results in Pancreatic cancer patients who have run out of treatment options

SYDNEY and NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- EnGeneIC, a pioneer in personalised cancer therapeutics, announces the publication of its clinical trial results in peer reviewed prestigious...
November 08, 2023 04:00 ET | Source: EnGeneIC

November is Pancreatic Cancer Awareness Month

SYDNEY, Australia and NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Pancreatic ductal adenocarcinoma (PDAC), which accounts for >90% of pancreatic tumors, is one of the most lethal malignancies and...
January 31, 2023 13:46 ET | Source: EnGeneIC

EnGeneIC publishes the COVID-EDV vaccine’s novel mechanism of action in a leading Immunology journal

Protects against mutant strainsPromotes a long term memory responseNo side effects in healthy volunteersVaccine stored and transported at room temperature with long shelf lifeSeeking...
June 28, 2022 07:00 ET | Source: EnGeneIC

EnGeneIC’s second generation COVID-19 vaccine protects against all variants

SYDNEY, Australia, June 28, 2022 (GLOBE NEWSWIRE) -- The world’s first COVID-19 vaccine to offer immunity against all variants is one step closer. Clinical trials have shown the novel vaccine works...
November 30, 2021 07:00 ET | Source: EnGeneIC

Australian Biotech EnGeneIC Strikes Landmark Deal with Major US Biotech ImmunityBio for COVID-19 Vaccine and Cancer Treatment

SYDNEY, Australia and NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Australian company EnGeneIC has announced a landmark deal with major US biotech ImmunityBio, over a ground-breaking approach to both...
September 07, 2021 22:26 ET | Source: EnGeneIC

Australian biotech, EnGeneIC, develops world-first nanocellular anti-COVID-19 vaccine that defeats mutant viruses and stimulates a broad anti-viral response

Works against mutant strains including DeltaNo need for refrigeration during transport and storage No added stabilisers or chemicals Safety and immune response clinical trial recruiting now in...